Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PYGB | P11216 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8039420 | 1.00 | CA2 (0.42) | CA2CA9CA12SMN1; SMN2PYGB | |
| SCHEMBL28984898 | 0.83 | FOLH1 (0.41) | CA2CA9CA12 | |
| SCHEMBL28419458 | 0.82 | PYGB (0.51) | CA2CA9CA12PYGBGAA | |
| SCHEMBL27997210 | 0.82 | PYGB (0.51) | CA2CA9CA12PYGBGAA | |
| SCHEMBL867964 | 0.82 | PYGB (0.51) | CA2CA9CA12PYGBGAA | |
| SCHEMBL3801496 | 0.82 | PYGB (0.51) | CA2CA9CA12PYGBGAA | |
| SCHEMBL2012475 | 0.82 | PYGB (0.51) | CA2CA9CA12PYGBGAA | |
| SCHEMBL20476841 | 0.82 | PYGB (0.51) | CA2CA9CA12PYGBGAA | |
| SCHEMBL29550937 | 0.80 | PYGB (0.49) | CA2CA9CA12PYGBGAA | |
| SCHEMBL30259669 | 0.80 | FOLH1 (0.40) | CA2CA9CA12SMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007256-B2 | Synthetic lipopeptide vaccines and immunotherapeutics | THE UNIVERSITY OF TOLEDO (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190231860-A1 | SYNTHETIC LIPOPEPTIDE VACCINES AND IMMUNOTHERAPEUTICS | THE UNIVERSITY OF TOLEDO (US) | 2019-08-01 | — | — | US | disclosed |
| WO-2018058086-A1 | SYNTHETIC LIPOPEPTIDE VACCINES AND IMMUNOTHERAPEUTICS | THE UNIVERSITY OF TOLEDO (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190231860-A1 | SYNTHETIC LIPOPEPTIDE VACCINES AND IMMUNOTHERAPEUTICS | LRBA, LY96, TSLP | CA2 4478/4885CA9 4314/4885CA12 2886/4885 |
| US-11007256-B2 | Synthetic lipopeptide vaccines and immunotherapeutics | LRBA, LY96, TSLP | CA2 4478/4885CA9 4314/4885CA12 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.